Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

56P - Prevalence, clinical characteristics, and treatment outcomes of patients with KRAS-mutated non-squamous NSCLC and PD-L1 expression: Real-life data analysis

Date

22 Mar 2024

Session

Poster Display session

Topics

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Jana Safrankova

Citation

Annals of Oncology (2024) 9 (suppl_3): 1-53. 10.1016/esmoop/esmoop102569

Authors

J. Safrankova1, L. Motta1, B. Pedrazzini1, F. Molinari2, A. Valera2, S. Epistolio2, S. Freguia2, G. Schiavone1, M. Frattini2, P.R. Froesch1

Author affiliations

  • 1 EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana, Bellinzona/CH
  • 2 Istituto Cantonale di Patologia, Locarno/CH

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 56P

Background

Lung adenocarcinoma is a complex and heterogeneous disease characterized by diverse molecular alterations. Programmed death-ligand 1 (PD-L1) expression is a crucial biomarker in treatment algorithms, yet its clinico-pathological correlations with other mutations remain unclear. This study aims to investigate the impact of PD-L1 expression on outcomes in patients with KRAS mutations.

Methods

A single-center retrospective cohort study included patients diagnosed with non-squamous NSCLC between January 2018 and July 2022. A targeted next-generation sequencing (NGS) analysis by Ion Torrent® (ThermoFisher Scientific) (Ion AmpliSeq CLv2 panel) was performed. PD-L1 expression was assessed by Immunohistochemistry (ab SP263), and patients were categorized into PD-L1 <1% (negative), 1-49% (intermediate), and ≥ 50% (high).

Results

Clinical data from 464 patients were collected, revealing KRAS mutations in 179 patients (38.6%). 77 (43%) had a co-mutation, most frequently TP53 (74%) and STK11 (14.3%). Others co-mutations (24.7%) include MET, BRAF, FGFR2, SMAD4, ERBB4, PTEN, CTNNB1, PIK3CA, FBXW7. PD-L1 expression in KRAS mut cohort was negative in 59 (33,7%), intermediate in 61 (34.8%) and high in 55 pts (31,4%); in KRAS WildType: negative in 109 (39.9%), intermediate in 105 (38.4%) and high in 59 pts (21,6%); in patients with KRAS and a co-mutation was: negative in 22 (29%), intermediate in 22 (29%) and high in 33 pts (43,4%). Our data shows a higher incidence of PD-L1 expression in KRAS-mutated patients compared to KRAS wild-type (p=0.02), especially when presenting a co-mutation (p=0.003). Analysis of progression-free survival (PFS) after the first line of treatment with immune checkpoint inhibitors (ICIs) in 30 pts with stage IV KRAS-mutated NSCLC and high PD-L1 showed a trend favoring patients presenting a co-mutation (mPFS 13.7mo KRAS co-mutated vs. 3.6mo in KRAS only; HR 0.26; CI 95% 0.09-0.070; p=0.19).

Conclusions

These findings emphasize the importance of further exploring PD-L1 role in KRAS mutated patients, especially by taking into account accompanying mutations in other genes evaluated by NGS.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.